Cigall Kadoch, associate professor and HHMI Investigator, Dana-Farber Cancer Institute and Harvard Medical School, and scientific founder of Foghorn Therapeutics (NASDAQ: FHTX), interviews Rick Young, professor of biology at MIT and member of the Whitehead Institute about the latest research and knowledge of how transcriptional regulation can be harnessed and targeted in drug development.